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Purpose: Luteolin exerts beneficial effects against obesity-associated comorbidities,
although its influence on vascular dysfunction remains undetermined. We examined the
effects of luteolin on endothelial dysfunction in a mouse model of diet-induced obesity.
Methods: Standard diet (SD) or high-fat diet (HFD)-fed mice were treated daily with
luteolin intragastrically. After 8 weeks, body and epididymal fat weight, as well as
blood cholesterol, glucose, and triglycerides were evaluated. Endothelium-dependent
relaxations of resistance mesenteric vessels was assessed by a concentration-response
curve to acetylcholine, repeated upon Nw-nitro-L-arginine methylester (L-NAME) or
ascorbic acid infusion to investigate the influence of nitric oxide (NO) availability
and reactive oxygen species (ROS) on endothelial function, respectively. Intravascular
ROS production and TNF levels were measured by dihydroethidium dye and ELISA,
respectively. Endothelial NO synthase (eNOS) and superoxide dismutase 1 (SOD1), as
well as microRNA-214-3p expression were examined by Western blot and RT-PCR
assays, respectively.
Results: HFD animals displayed elevated body weight, epididymal fat weight and
metabolic indexes. Endothelium-dependent relaxation was resistant to L-NAME and
enhanced by ascorbic acid, which restored also the inhibitory effect of L-NAME,
suggesting a ROS-dependent reduction of NO availability in HFD vessels. Moreover,
media-lumen ratio, intravascular superoxide anion and TNF levels were increased,
while vascular eNOS, SOD1, and microRNA-214-3p expression were decreased. In
HFD mice, luteolin counteracted the increase in body and epididymal fat weight, and
metabolic alterations. Luteolin restored vascular endothelial NO availability, normalized
the media-lumen ratio, decreased ROS and TNF levels, and normalized eNOS, SOD1
and microRNA-214-3p expression.
Conclusion: Luteolin prevents systemic metabolic alterations and vascular dysfunction
associated with obesity, likely through antioxidant and anti-inflammatory mechanisms.
Keywords: obesity, high-fat diet, mice, vascular dysfunction, oxidative stress, inflammation, luteolin
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INTRODUCTION
Obesity represents a major public health and economic problem
of global significance that reflects behavioral changes in modern
society, including the greater intake of fat-rich food and sedentary
lifestyle (World Health Organization [WHO] and Global Health
Observatory [GHO], 2014). Obesity is a challenge for global
public health, particularly with regard for its implications
in several chronic diseases, including cardiovascular diseases
(Poirier et al., 2006). Over the last two decades, it has
been increasingly recognized that the excessive accumulation
of adipose tissue exerts remarkable adverse effects on the
vascular system (Poirier et al., 2006; Virdis et al., 2011).
In particular, perivascular adipose tissue (PVAT) can directly
modulate vascular tone through the secretion of a variety of
pro-inflammatory cytokines that in turn give rise to oxidative
stress, thereby impairing vascular function (Elmarakby and
Imig, 2010; Chatterjee et al., 2013; Virdis, 2016; Reho and
Rahmouni, 2017). Of note, endothelial dysfunction, which is
an early manifestation of altered vascular homeostasis due to
exposure to cardiovascular risk factors, is a predictive index of
cardiovascular events in high-risk patients (Lerman and Zeiher,
2005). Indeed, endothelial dysfunction is generally characterized
by an increased level of vascular wall oxidative stress, supported
mainly by reactive oxygen species (ROS). This leads to a greater
NO consumption, resulting ultimately in an impairment of
endothelial-dependent vasorelaxation (Furukawa et al., 2004;
Heistad, 2006; Munzel et al., 2010; Sena et al., 2013). Data from
animal studies have provided compelling evidence that high-fat
diet (HFD) leads to both functional and structural changes in
the vasculature. In particular, HFD-induced obesity has been
reported to alter vascular reactivity (vasoconstriction) and to
increase cardiac mass in mice (Calligaris et al., 2013), along with
an increase in both inflammation and oxidative stress, strongly
implicated in the onset of endothelial dysfunction (Gamez-
Mendez et al., 2015).
Currently, there is a great interest in the therapeutic
potential of curative plants. Their beneficial effects have been
largely attributed to their contents in phenolic compounds,
with particular regard for flavonoid derivatives endowed
with antioxidant and anti-inflammatory properties (Siasos
et al., 2013). Both clinical and animal studies have suggested
that antioxidant-rich diets could protect against free radical
production and oxidative damage, with a consequent prevention
of obesity and related comorbidities (Gentile et al., 2018).
Luteolin, known as 3′,4′,5,7-tetrahydroxyflavone, is one of
the most common polyphenolic flavonoids present in several
medicinal herbs, fruits and vegetables (Lopez-Lazaro, 2009).
Luteolin exerts a variety of pharmacological actions, including
antioxidant, anti-inflammatory, antimicrobial, and anticancer
effects (Lopez-Lazaro, 2009). Previous in vitro and in vivo
investigations documented its beneficial effects on inflammation
and oxidative stress associated with cardiovascular diseases (Qian
et al., 2010; Si et al., 2014; Jia et al., 2015).
Recent data suggested also that this flavonoid reduces hepatic
steatosis and insulin resistance (El-Bassossy et al., 2013; Xu
et al., 2014; Kwon et al., 2015), inhibits cholesterol biosynthesis
(Gebhardt, 2002) and increases endothelial NO synthase (eNOS)
gene expression (Li et al., 2004). However, the effects of luteolin
on obesity-related endothelial dysfunction have not been clarified
yet. Therefore, in this study we investigated the impact of luteolin
on endothelial dysfunction in a mouse model of diet-induced
obesity. Of note, the HFD mouse model is routinely employed
to assess the pathophysiological complications associated with
obesity, such as cardiovascular disorders and, more specifically,
those related to endothelial functions (Rosini et al., 2012). In
this respect, data obtained from these mice have a valuable
translational potential for human settings.
MATERIALS AND METHODS
Animals
All experiments were approved by the Ethical Committee
for Animal Experimentation at the University of Pisa and
the Italian Ministry of Health (authorization n◦744/2015-PR).
Animal care and handling were carried out in accordance with
the indications of the European Community Council Directive
2010/63/UE, recognized and adopted by the Italian Government.
Experiments were performed on six-week-old male C57BL/6
mice (20–22 g body weight) purchased from ENVIGO Srl (San
Pietro al Natisone, Italy). Mice were housed for 1 week in
stainless-steel cages in a temperature-controlled (22–24◦C) room
with a 12:12 h light/dark cycle and 50–60% relative humidity.
Mice were allowed access to diets and water ad libitum. At
the end of in vivo procedures, animals were fasted overnight,
anaesthetized using chloral hydrate, and sacrificed by cervical
dislocation. Blood samples (50 µl) were taken by tail incision
and collected in tubes containing heparin to analyze systemic
metabolic parameters. Epididymal adipose tissue was removed
and weighted. Mesenteric vessels were rapidly excised, cleaned
of connective tissue and used for the functional evaluation
of endothelium-dependent and -independent relaxation. Other
portions of mesenteric arteries were stored at−80◦C until needed
for further analysis.
Experimental Procedures
To induce obesity, mice were fed with HFD (60% kcal from
fat, TD 06414) for 8 weeks. Control animals remained on SD
(18% kcal from fat; TD 2018), which was initially administered
to all mice during the first week after their delivery to the
laboratory. HFD provided 18.3% kcal as proteins, 21.4% kcal
as carbohydrates and 60.8% kcal as fat (5.1 kcal/g), whereas
SD provided 24% kcal as proteins, 58% kcal as carbohydrates
and 18% kcal as fat (3.1 kcal/g). Subgroups of mice fed
with SD or HFD were randomly assigned to one of the four
experimental groups (n = 5 per group): (1) SD; (2) SD treated with
luteolin (10 mg/Kg/day); (3) HFD; (4) HFD treated with luteolin
(10 mg/Kg/day). Luteolin (Sigma Chemicals Co., St. Louis, MO,
United States) or its vehicle (0.3% carboxymethylcellulose) was
administered by oral gavage once daily, starting the first day of
HFD administration, and its dose was selected in accordance with
a previous report (Liu et al., 2014). Throughout the experimental
period, changes in body weight were recorded weekly.
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Blood Cholesterol, Triglycerides, and
Glucose Determinations
Total blood cholesterol, triglycerides, and glucose were assayed
using MULTICARE IN (Biochemical Systems International Srl,
Arezzo, Italy) in accordance with the manufacturer’s protocols.
Preparation of Small Mesenteric Arteries
for Functional Experiments
After dissection, the first branch of mesenteric artery was placed
in cold (4◦C) physiological salt solution (PSS) containing (in
mmol/L): NaCl 120, NaHCO3 25, KCl 4.7, KH2PO4 1.18, MgSO4
1.18, CaCl2 2.5, EDTA 0.026, and glucose 5.5, as previously
published (Virdis et al., 2003). A second-order branch of the
mesenteric arterial tree (≈2 mm in length) was dissected and
mounted on 2-glass microcannule in a pressurized myograph,
as previously described (Virdis et al., 2007). Vessels were
equilibrated for 60 min under constant intraluminal pressure
(45 mmHg) in warmed (37◦C) and bubbled (95% air and
5% CO2) PSS, at pH 7.4. Vessels were considered viable and
used if they constricted >70% of their resting lumen diameter
in response to an extraluminal application of high-potassium
solution (125 mmol/L of KCl) containing 100 µmol/L of
noradrenaline (NA).
Vascular Remodeling and Endothelial
Function
Endothelial-dependent and independent vasorelaxation in all
experimental groups (n = 5 each group) were defined
by the vasodilatory response to cumulative concentrations
of Ach (0.001–100 µM) and sodium nitroprusside (0.01–
100 µM), respectively. All experiments were performed in vessels
precontracted with NA (10 µM). To ensure an equal NA-induced
contractility in vessels from SD, SD treated with luteolin, HFD
and HFD treated with luteolin mice, we performed preliminary
experiments to assess the amount of vasoconstriction induced
by increasing NA concentrations (from 1 nM to 100 µM). The
results of these experiments showed that NA 10 µmol/L was able
to elicit similar contractions among different groups (data not
shown), thus such a concentration was selected for functional
experiments.
To evaluate the proportion of endothelial-dependent
vasodilation due to NO availability, concentration-response
curves ACh were constructed after 30 min pre-incubation with
FIGURE 1 | (A) Body weight gain (%) in mice fed with SD, SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD plus treatment with luteolin (10 mg/Kg/day)
for 8 weeks. Each point represents the mean ± SEM of five animals. aP < 0.05 significant difference vs. SD at the respective week; ∗P < 0.05 significant difference
vs. HFD at the respective week. (B) Epididymal fat weight in mice fed with SD, SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD plus treatment with
luteolin (10 mg/Kg/day) for 8 weeks. Each column represents the mean ± SEM of five animals. cP < 0.001, significant difference vs. SD; #P < 0.001 significant
difference vs. HFD. Statistics: two-way analysis of variance followed by Newman–Keuls test.
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the NOS inhibitor Nw-nitro-L-arginine methylester [(L-NAME)
100 µM, Sigma Co., St. Louis, MO, United States]. To assess the
influence of ROS on NO availability, concentration-response
curves to ACh were repeated in the presence of the antioxidant
ascorbic acid (100 µM, Sigma, 30-min pre-incubation). Finally,
to estimate whether ROS generation could impair NO-mediated
endothelium-dependent relaxation, ACh was infused during
simultaneous incubation with L-NAME and ascorbic acid.
Vessels were then deactivated by perfusion with Ca2+-free PSS
containing 10 mmol/L EGTA for 30 min. Media thickness and
lumen diameter were measured in three different points from
each small artery to obtain the media-lumen ratio (M/L), with
intraluminal pressure at 45 mmHg (Virdis et al., 2003). Media
cross-sectional area (MCSA) was obtained by subtraction of the
internal from the external cross-sectional areas using external
plus lumen diameters, as previously described (Bruno et al.,
2017).
Detection of Vascular Superoxide Anion
Generation
The in situ production of superoxide anion from 30 mm
frozen mesenteric vessel sections was evaluated at the confocal
microscope by means of the fluorescent dye dihydroethidium
[(DHE), Sigma], as previously described (Virdis et al., 2015).
Three slides per segment were analyzed simultaneously after
incubation with Krebs solution at 37◦C for 30 min. Krebs-HEPES
buffer containing 2 µM DHE was then applied to each section
and evaluated under fluorescence microscopy. In the presence
of superoxide, DHE undergoes oxidation and intercalates in
cell DNA, thus staining the nucleus with red fluorescence
(excitation at 488 nm, emission 610 nm). The percentage of
arterial wall area stained with the red signal was normalized to
the total area examined and quantified using an imaging analysis
software (McBiophotonics Image J; National Institutes of Health,
Bethesda, MD, United States).
Assay of TNF in Mesenteric Arteries
Tissue TNF levels were measured with enzyme-linked
immunosorbent assay (ELISA) kit (BioSource International,
Camarillo, CA, United States), as previously described (Antonioli
et al., 2010). For this purpose, mesenteric vessels (30 mg), stored
previously at −80◦C, were weighed, thawed, and homogenized
in 300 µl of ice-cold lysis buffer (200 mM NaCl, 5 m MEDTA,
10 mMTris, 10% glycerine, 1 mM phenylmethylsulfonyl
fluoride, 1 mg/ml leupeptin, and 28 mg/ml aprotinin,
pH 7.4), and centrifuged at 13,400g for 20 min. Aliquots
(100 µl) of the supernatants were then used for assay. Tissue
TNF levels were expressed as picogram per milligram of
tissue.
Western Blot Analysis
Samples of mesenteric arteries were homogenized using an
assay lysis buffer (Protease Inhibitor Cocktail Tablet, Roche,
Indianapolis, IN, United States). Homogenates were spun by
centrifugation at 20,000 rpm for 15 min at 4◦C. Supernatants
were then separated from pellets and stored at −80◦C. Protein
FIGURE 2 | (A) Total cholesterol, (B) glucose, and (C) triglycerides in mice fed
with SD, SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD plus
treatment with luteolin (10 mg/Kg/day) for 8 weeks. Each column represents
the mean ± SEM of five animals. aP < 0.05, bP < 0.01 significant difference
vs. SD; ∗P < 0.05, $P < 0.01 significant difference vs. HFD. Statistics:
two-way analysis of variance followed by Newman–Keuls test.
concentration was determined by the Bradford method
(Protein Assay Kit; Bio-Rad, Hercules, CA, United States).
Equivalent amounts of protein lysates (50 µg) were separated
by 4–10% SDS–PAGE for immunoblotting. After transfer
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FIGURE 3 | Endothelial-dependent relaxations of mesenteric resistance arteries to acetylcholine in mice fed with SD (A), SD plus treatment with luteolin
(10 mg/Kg/day) (B), HFD (C), or HFD plus treatment with luteolin (10 mg/Kg/day) (D) for 8 weeks. Each point represents the mean ± SEM of five animals.
aP < 0.05, bP < 0.01 significant difference vs. saline. Statistics: two-way analysis of variance followed by Newman–Keuls test.
onto a polyvinylidene fluoride membrane, the blots were
blocked and incubated overnight with rabbit anti-eNOS [NOS3
(C20): SC-654; Santa Cruz Biotechnology, Santa Cruz, CA,
United States] or anti-SOD1 antibodies [SOD1: GTX100554;
GeneTex, Irvine, CA, United States]. After repeated washings
with Tris-Buffered saline and Tween 20 buffer, appropriate
secondary peroxidase-conjugated antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, United States) were added
for 1 h at room temperature. Immunoreactive bands were
then visualized by incubation with chemiluminescent reagents
(Immobilon reagent; Millipore, Billerica, MA, United States)
and examined by Kodak Image Station 440 (Celbio, Milan,
Italy) for signal detection. To ensure equal sample loading,
blots were stripped and reprobed for determination of
β-actin by a specific antibody (P5747; Sigma-Aldrich, Milan,
Italy).
Evaluation of Tissue miR-214-3p
Expression
Total microRNAs were extracted and purified from frozen
mesenteric vessels by using miRNeasy Mini Kit (Qiagen,
Germany). Reverse transcription of the extracted miRNAs
was performed by the miScript Reverse Transcription Kit
(Qiagen, Germany). cDNA was diluted 1:3 in RNase-free
water and then qPCRs were performed in triplicate using
the miScript SYBR-Green PCR kit (Qiagen, Germany) on
the MiniOpticon CFX 48 real-time PCR Detection System
(Bio-Rad, Hercules, CA, United States). MiScript Primer
TABLE 1 | Morphological characteristics and maximal relaxation (%) to acetylcholine ± L-NAME, ascorbic acid or both of mesenteric vessels from the four groups.
Lumen
diameter (µm)
Media thickness
(µm)
Acetylcholine Acetylcholine+
L-NAME
Acetylcholine+
Ascorbic Acid
Acetylcholine+
Ascorbic Acid
+ L-NAME
SD 262.3 ± 3.8 15.7 ± 0.2 97.1 ± 0.5 51.3 ± 0.8 97.4 ± 0.7 47.1 ± 1.6
SD + luteolin 260.4 ± 4.2 15.6 ± 0.4 96.5 ± 0.6 51.0 ± 0.7 96.3 ± 0.4 50.7 ± 0.8
HFD 217.4 ± 4.8∗ 18.5 ± 0.2∗ 53.0 ± 0.2∗ 44.3 ± 1.8 96.7 ± 0.2 52.1 ± 0.5
HFD + luteolin 237.7 ± 15.8 15.4 ± 0.9 80.7 ± 0.7 49.1 ± 0.8 97.5 ± 0.4 50.9 ± 0.3
Data are expressed as mean ± SEM. ∗P < 0.01 vs. other groups Statistics: two-way analysis of variance followed by Newman–Keuls test.
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FIGURE 4 | Media-lumen ratio of mesenteric arteries from mice fed with SD,
SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD plus treatment
with luteolin (10 mg/Kg/day) for 8 weeks. Each column represents the
mean ± SEM of five animals. cP < 0.001, significant difference vs. SD;
#P < 0.001 significant difference vs. HFD. Statistics: two-way analysis of
variance followed by Newman–Keuls test.
Assays specific for mmu-miR-214-3p (MIMAT0000661),
mmu-SNORD6 and mmu-RNU6 were obtained from Qiagen.
miR-214-3p expression was calculated using Ct method and
normalized to the expression of two housekeeping, SNORD6 and
RNU6.
Statistical Analysis
All data sets were represented as the mean ± standard error
of mean (SEM). Comparisons of results among groups were
carried out by two-way analysis of variance (ANOVA) followed
by Newman–Keuls multiple-comparison post hoc test. A P-value
<0.05 was considered as statistically significant. Maximal
Ach- and sodium nitroprusside-induced relaxant responses
(Emax) were calculated as maximal percentage increments of
lumen diameter. All statistical analyses were performed using
GraphPad Prism, version 5.0 (GraphPad Software Inc., San
Diego, CA, United States).
RESULTS
Body and Epididymal Fat Weight
A significant increase in body weight was observed in HFD
as compared with SD mice (Figure 1A). Luteolin significantly
counteracted the body weight gain in HFD mice (Figure 1A).
In animals fed with SD, luteolin did not modify the pattern of
body weight gain throughout 8 weeks, as compared with control
SD animals (Figure 1A). In HFD mice the weight of epididymal
fat significantly increased as compared to SD animals, and this
FIGURE 5 | (A) Representative dihydroethidium (DHE) staining and (B)
quantitative analysis (bar graph) of the red signal in mesenteric arteries
(magnification ×40) from mice fed with SD, SD plus treatment with luteolin
(10 mg/Kg/day), HFD or HFD plus treatment with luteolin (10 mg/Kg/day) for
8 weeks. Each column represents the mean ± SEM of five animals.
cP < 0.001, significant difference vs. SD; #P < 0.001 significant difference vs.
HFD. Statistics: two-way analysis of variance followed by Newman–Keuls test.
effect too was counteracted by luteolin (Figure 1B). By contrast,
epididymal fat weight did not differ when comparing SD and
luteolin treated-SD mice (Figure 1B).
Total Cholesterol, Triglycerides, and
Glucose Levels
High-fat diet resulted in a significant increase in total
cholesterol, glucose, and triglycerides levels as compared with
SD (Figures 2A–C). Administration of luteolin to HFD mice
prevented partly these metabolic alterations (Figures 2A–C).
No significant differences in these parameters were observed by
comparison of SD and luteolin treated-SD mice at the end of the
study (Figures 2A–C).
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Endothelium-Dependent Vascular
Relaxation and Remodeling
In mesenteric vessels from SD, relaxation to ACh was significantly
attenuated by L-NAME (100 µM), and not affected by ascorbic
acid (100 µM) (Figure 3A). Treatment of SD mice with luteolin
did not modify the patterns of responses to ACh in mesenteric
vessels, in the absence or in the presence of ascorbic acid or
L-NAME (Figure 3B). Mesenteric vessels from HFD mice showed
a reduced vasorelaxation to ACh as compared to SD animals,
and also the inhibitory effect of L-NAME on ACh-induced
relaxation was significantly attenuated as compared to SD
mice. ACh-dependent relaxation in HFD mice was improved
by pre-incubation with ascorbic acid, which restored also the
inhibitory effect of L-NAME (Figure 3C). By contrast, luteolin
enhanced the relaxation to ACh in mesenteric vessels from
HFD mice and restored the inhibitory effect of L-NAME on
ACh-induced relaxation (Figure 3D). Endothelium-independent
maximal relaxation by sodium nitroprusside was similar in all
groups (SD: 96.4 ± 1.6%; SD+luteolin: 97.1 ± 1.1%; HFD:
97.3± 1.2%; HFD+luteolin: 96.7± 1.8%; P = NS).
In keeping with the endothelial function results, media-lumen
ratio was significantly increased in HFD mice. The impact
of HFD on vascular remodeling and endothelial function was
counteracted by luteolin, so that HFD mice supplemented with
luteolin showed an endothelial function and media-lumen ratio
similar to that of SD mice and significantly improved compared
to HFD animals (Table 1 and Figure 4).
Vascular Superoxide Anion Generation
Dihydroethidium assay revealed a significant increase in
superoxide anion production in vessels from HFD mice as
compared with SD controls (Figures 5A,B). While in SD
mice luteolin did not modify superoxide anion generation
(Figures 5A,B), in HFD mice luteolin treatment counteracted
significantly such an increment (Figures 5A,B).
TNF Levels in Mesenteric Arteries
TNF levels in mesenteric vessels from HFD mice were
significantly increased, as compared with SD animals (Figure 6).
Treatment of HFD mice with luteolin decreased TNF levels
toward control values, while the flavonoid did not produce any
significant effect in SD mice (Figure 6).
Vascular eNOS and SOD1 Expression
Endothelial NO synthase expression in mesenteric vessels was
significantly attenuated in HFD mice, as compared with SD
animals (Figure 7). In SD mice, luteolin did not modify the
expression of eNOS (Figure 7). Luteolin administration to HFD
mice restored the levels of vascular eNOS expression (Figure 7).
The expression of SOD1 was significantly reduced in
mesenteric vessels from mice fed with HFD, as compared with
control animals (Figure 8). In animals fed with SD, luteolin did
not modify the expression pattern of SOD1, while in HFD mice
the flavonoid restored SOD1 expression (Figure 8).
FIGURE 6 | TNF levels in mesenteric arteries obtained from mice fed with SD,
SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD plus treatment
with luteolin (10 mg/Kg/day) for 8 weeks. Each column represents the
mean ± SEM of five animals. aP < 0.05, significant difference vs. SD;
∗P < 0.05, significant difference vs. HFD. Statistics: two-way analysis of
variance followed by Newman–Keuls test.
miR-214-3p Expression
miR-214-3p expression was significantly downregulated in
mesenteric vessels from HFD, as compared to levels found in
SD mice (Figures 9A,B). In SD mice, luteolin did not influence
miR-214-3p in mesenteric vessels (Figures 9A,B). In HFD mice,
luteolin counteracted significantly the decreased expression of
miR-214-3p (Figures 9A,B). These results were confirmed by
normalization vs. the housekeeping genes, SNORD6 and RNU6.
DISCUSSION
This study provides the first experimental evidence that luteolin
is able to prevent weight gain, metabolic alterations, endothelial
dysfunction and vascular remodeling related to HFD-induced
obesity. We show also that the benefits of luteolin on endothelial
function and vascular remodeling are likely mediated by its
anti-oxidant and anti-inflammatory properties, resulting in a
preserved NO availability within the vascular wall. Obesity
is a major risk factor for health, as it is associated with
a significant increase in morbidity, mortality and economic
costs for healthcare systems (Berrington de Gonzalez et al.,
2010). Cardiovascular disease represents the most important
complication associated with obesity and the development of
endothelial dysfunction combined with vascular remodeling are
the earliest manifestations of an altered vascular homeostasis,
involved in the initiation, evolution, and complications of
cardiovascular disorders. Thus, if the results provided by our
study could be translated to humans, luteolin might become
an important tool for treatments aimed at preventing obesity
and its related complications. Of note, besides the beneficial
effects exerted by luteolin on endothelial function, it is likely
that its anti-inflammatory and antioxidant effects could take
a part in the improvement of metabolic syndrome, and
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FIGURE 7 | Western blot analysis of eNOS expression in mesenteric arteries from mice fed with SD, SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD
plus treatment with luteolin (10 mg/Kg/day) for 8 weeks. The figure displays representative blots and column graph referring to the densitometric analysis of
immunoreactive bands of eNOS normalized to the expression of β-actin. Each column represents the mean ± SEM of five animals. cP < 0.001, significant difference
vs. SD; #P < 0.001 significant difference vs. HFD. Statistics: two-way analysis of variance followed by Newman–Keuls test.
particularly the diabetic condition, associated with HFD, as
also previously reported (Deqiu et al., 2011; Bansal et al.,
2012).
The experimental model of diet-induced obesity has been
shown to be suitable for investigations on the pathophysiology
of complications associated with obesity, such as metabolic
syndrome and cardiovascular disorders and, more specifically,
those related to endothelial function (Rosini et al., 2012).
Furthermore, among the obesogenic diets, HFD contributes
significantly to weight gain, the consequent development of
obesity, and related disorders (Mozaffarian et al., 2011). Our
results are in keeping with previous observations (Antonioli et al.,
2017), confirming that mice fed with HFD for 8 weeks developed
a marked increase in body and epididymal fat weight associated
with an elevation of total cholesterol, triglycerides, and glucose,
thus corroborating further the suitability of this experimental
model.
Interestingly, our results from functional experiments
indicated that mesenteric small arteries from HFD animals
display altered endothelium-dependent relaxations due to a
reduced NO availability. Such a deficiency is likely to depend
on an increased intravascular ROS generation, as documented
by the restored response to ACh after preincubation with
ascorbic acid, and the increased DHE fluorescence in the
vascular wall from HFD as compared to SD mice. In particular,
superoxide anion overproduction has been previously shown
to take a significant part in the development of endothelial
dysfunction, through the reaction with NO and subsequent
production of peroxynitrite (Fukai and Ushio-Fukai, 2011). In
our experiments, we observed that the expression of SOD1, a
key enzyme involved in the neutralization of superoxide anions
(Fukai and Ushio-Fukai, 2011), was significantly decreased in
mesenteric vessels from HFD-fed mice, thus suggesting that
the endothelial dysfunction elicited by HFD could depend
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FIGURE 8 | Western blot analysis of SOD1 expression in mesenteric arteries from mice fed with SD, SD plus treatment with luteolin (10 mg/Kg/day), HFD or HFD
plus treatment with luteolin (10 mg/Kg/day) for 8 weeks. The figure displays representative blots and column graph referring to the densitometric analysis of
immunoreactive bands of SOD1 normalized to the expression of β-actin. Each column represents the mean ± SEM of five animals. aP < 0.05, significant difference
vs. SD; ∗P < 0.05 significant difference vs. HFD. Statistics: two-way analysis of variance followed by Newman–Keuls test.
also on the reduced ability of vascular tissues to scavenge
superoxide anions. In agreement with our results, recent
reports have documented a marked endothelial dysfunction
associated with a significant vascular pro-oxidant condition
in HFD animals (Ketonen et al., 2010; Heinonen et al., 2014;
Toral et al., 2015), as well as a decreased SOD1 scavenging
activity (Mo et al., 2018). Moreover, evidence from clinical
studies, showing a correlation of obesity with compromised
vascular function, is available also. Romero-Corral et al. (2010)
showed that an 8-week overfeeding period increased visceral
adiposity and resulted in an impairment of endothelial function
in humans. The authors observed, as a proof-of-concept,
that the impairment of endothelial function was reversible
when the visceral fat was reduced by pre-planned caloric
restriction (Romero-Corral et al., 2010). Virdis et al. (2011)
have shown that vessels from obese individuals displayed a
blunted endothelium-dependent relaxation, caused by a reduced
NO availability. Of note, alterations were reversed by either a
superoxide scavenger or a TNF inhibitor, suggesting a key role of
oxidative stress as well as of vascular inflammation (Virdis et al.,
2011). With regard to the latter aspect, our data on TNF levels
in mesenteric arteries from HFD mice confirmed a condition
of obesity-related low-grade inflammation that may lead to an
increase in oxidative stress, thus exerting detrimental effect on
endothelial function.
In view of the pathophysiological role of eNOS in obesity,
whole-body metabolism and vascular function (Sansbury and
Hill, 2014), we evaluated eNOS levels within the vascular
wall. As expected, HFD mice showed a lower eNOS protein
expression as compared to SD mice. However, such a decrease
does not seem to take a significant part in the altered
endothelium-dependent relaxation observed in HFD animals,
since the in vitro antioxidant effect exerted by ascorbic acid
was able per se to restore the vasorelaxant effect of ACh in
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FIGURE 9 | Relative expression of miR-214-3p, normalized vs. the
housekeeping genes SNORD6 (A) or RNU6 (B), in mesenteric vessels from
mice fed with SD, SD plus treatment with luteolin (10 mg/Kg/day), HFD or
HFD plus treatment with luteolin (10 mg/Kg/day). Each column represents the
mean ± SEM of five animals. cP < 0.001, bP < 0.01 significant difference vs.
SD, $P < 0.01 significant difference vs. HFD. Statistics: two-way analysis of
variance followed by Newman–Keuls test.
HFD mice. Thus, these data suggest that, under antioxidant
conditions, the residual level of eNOS expression in HFD vessels
is able to ensure an NO production sufficient to elicit a complete
vasodilation. Nevertheless, the decreased expression of eNOS in
HFD mice could be strongly related to the pathophysiology of
obesity and metabolic function. In support of this concept, it
is documented that eNOS abundance is decreased remarkably
in obese and diabetic humans and rodents, thus suggesting its
central role in regulating body composition (Sansbury and Hill,
2014). Moreover, evidence from an in vivo study showed that an
increased eNOS expression prevented the obesogenic effects of
HFD (Sansbury et al., 2012).
Among the different pathways, which could contribute to
vascular remodeling, we decided to investigate on miRNAs,
since they are increasingly recognized as key regulators of
important cardiac physiological processes, but are implicate
also in the pathological progression of cardiovascular diseases.
The significant downregulation of miR-214-3p, as observed
in mesenteric arterioles from HFD mice, might be important
in mediating the impact of HFD on endothelial function. As
documented by other authors, miR-214 undergoes modulation
under several pathological conditions, and it contributes to
the pathogenesis of various human disorders, including cancer
and cardiovascular diseases (Zhao et al., 2017). Moreover, miR-
214 expression was reported to be decreased in senescent
endothelial cells, in which a lowered eNOS protein level
was documented as well (Rippe et al., 2012). The inverse
correlation between miR-214 and eNOS expression, reported,
by contrast, by Chan et al. (2009) might be related to
the “young” population of endothelial cells. In this regard,
Zhao et al. (2017) had previously suggested that miR-
214 might have opposite effects on “young” vs. “mature”
endothelial cells with regard for angiogenesis (inhibition vs.
promotion).
Endothelial dysfunction, being a functional reversible
alteration, represents an attractive target for prevention strategies
against cardiovascular diseases. Most recent studies on the
management of obesity and related disorders have been focused
on the potential role of plant compounds, with particular
regard for polyphenols. In this context, luteolin, a food-derived
flavonoid natural compound, is particularly attractive. Luteolin
is present in medicinal plants as well as in some vegetables
and spices, and it has received wide attention for its antitumor,
antioxidant, and anti-inflammatory effects as well as its capacity
to improve vascular functions in in vitro studies (Pietta,
2000).
Based on the above considerations, the second part of
the present study was dedicated to investigate the effects of
luteolin in counteracting the endothelial dysfunctions associated
with HFD-induced obesity. Notably, in mice fed with HFD,
luteolin was effective in counteracting the increase in body and
epididymal fat weight, as well as in reducing the elevations of
blood total cholesterol, triglycerides, and glucose. These findings
support previous observations highlighting an ameliorative effect
of luteolin in obese mice in terms of weights of body, liver, white
adipose tissue and elevated plasma lipids (Liu et al., 2014; Kwon
et al., 2015).
Of interest, in our experiments, luteolin was effective also
in mitigating vascular dysfunction. In particular, vessels from
HFD mice treated with luteolin showed an improved relaxation
to ACh, which became sensitive to L-NAME, while ascorbic
acid was no longer able to affect the vascular response to
ACh. The demonstration that, in the presence of luteolin,
L-NAME counteracted the relaxation to ACh, an effect not
exerted under baseline conditions, implies that NO availability
was restored after treatment with this flavonoid. It is worth noting
that, following luteolin administration, the restored inhibiting
effect of L-NAME on ACh was similar to that observed after
acute exposure to ascorbic acid at baseline, thus suggesting an
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antioxidant property of luteolin. In our results, this concept
is strengthened also by the luteolin ability of attenuating the
intravascular superoxide excess in HFD mice. Of note, this
antioxidant effect could also derive from the ability of luteolin
to counteract the HFD-induced decrease in SOD1 expression
in mesenteric vessels. Our data are supported by previous
observations, indicating luteolin as a vascular protective agent
that stimulates NO-dependent vascular dilatation by acting on
vascular endothelial cells (Si et al., 2014). Moreover, luteolin was
found to improve the ventricular function and coronary flow
throughout reperfusion, to increase the cardiac tissue viability
and enhance the manganese superoxide dismutase activity in
diabetic rats (Yang et al., 2015), as well as to protect rat
mesenteric arteries from injury by superoxide anion (Ma et al.,
2008).
In our experiments luteolin reduced TNF levels in mesenteric
arteries from HFD mice, thus suggesting an anti-inflammatory
activity. In agreement with our data, the ability of luteolin
in mitigating pro-inflammatory processes has been previously
described in the prevention of TNF-induced vascular
inflammation in both endothelial cells and mice (Jia et al., 2015).
In particular, it was shown that luteolin attenuated vascular
inflammation by suppressing TNF-stimulated expression of
chemokines and adhesion molecules, as well as preventing
the activation of nuclear factor (NF)-κB signaling in both
experimental models (Jia et al., 2015). Moreover, in an another
study, luteolin was found to reduce mRNA expression of
pro-inflammatory cytokines such as TNF and interleukin (IL)-6
in palmitic acid-induced IκB kinase (IKKb)/NF-kB activation in
human umbilical vein endothelial cells (HUVECs) (Deqiu et al.,
2011).
In the present study, luteolin administration to HFD mice
restored the levels of eNOS expression within vascular wall, in
keeping with previous evidence, showing that luteolin prevented
the decrease of eNOS expression induced by palmitic acid in
HUVECs (Deqiu et al., 2011). However, the effects of luteolin
on eNOS expression observed in HFD mice, does not seem to
account significantly for the beneficial effects of the flavonoid
on functional endothelium-dependent relaxation of mesenteric
arteries. Indeed, functional data showed that the relaxation of
mesenteric arteries was not restored by luteolin, while it is
reestablished by ascorbic acid, suggesting an involvement of
oxidative stress. Therefore, the ability of luteolin to increase
eNOS expression could take a significant part in mediating
its anti-obesogenic effects (Sansbury et al., 2012; Sansbury and
Hill, 2014), rather than an active involvement in counteracting
endothelial dysfunction.
Finally, in our experiments, luteolin was able to counteract the
decreased expression of miR-214-3p in mesenteric vessels from
HFD mice, likely due to its ability in regulating the inflammatory
changes induced by HFD. Moreover, our observation supports
the evidence, made by Rippe et al. (2012) that parallel changes
in eNOS and miRNAs expression in endothelial cells can be
involved in vascular dysfunction.
CONCLUSION
The present results suggest that luteolin can prevent systemic
metabolic alterations and vascular dysfunction associated with
obesity, likely through both antioxidant and anti-inflammatory
properties.
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